Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Jagsonpal Pharmaceuticals Ltd

| Financial Results for the Quarter and Year Ended March 31, 2026

Report Source

⬤27th Apr 26

Summary : Jagsonpal Pharmaceuticals reported increased operational profit, declared a dividend, approved a share buyback, and expanded its market presence through acquisition, despite an exceptional expense from new labor codes.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Cost of materials consumed: 161.13 million (FY26).
  2. Purchases of stock-in-trade: 891.88 million (FY26).
  3. Employee benefits expense: 707.40 million (FY26).
  4. Depreciation and amortisation expense: 94.44 million (FY26).
  5. Other expenses: 540.36 million (FY26).
  6. Revenue from operations: 2,872.25 million (FY26) vs 2,687.16 million (FY25).
  7. Net cash from operating activities: 468.12 million (FY26) vs 551.13 million (FY25).
  8. Net cash used in investing activities: (356.49) million (FY26) vs (451.47) million (FY25).
  9. Net cash used in financing activities: (121.49) million (FY26) vs (116.98) million (FY25).
  10. Cash and cash equivalents at year-end: 100.42 million (FY26) vs 110.28 million (FY25).
  11. Total Assets: 3,166.77 million (FY26) vs 2,782.60 million (FY25).
  12. Total Equity: 2,761.72 million (FY26) vs 2,399.50 million (FY25).
  13. Non-current assets: 1,735.88 million (FY26) vs 1,170.66 million (FY25).
  14. Current assets: 1,430.89 million (FY26) vs 1,611.94 million (FY25).
  15. Audited Standalone Financial Results.

Corporate Overview

  1. Customers in India and overseas.
  2. Manufacturing and trading of pharmaceutical products, including active pharmaceutical ingredients.
  3. Single reportable business segment: pharmaceutical products.
  4. Acquired India and Bhutan business of Yash Pharma Laboratories Private Limited.
  5. Acquisition provides access to dermatology and childcare products.
  6. Strategic goal to broaden presence in the Indian market.

Risk Factors

  1. Impact of new labor codes on employee benefits.
  2. Risk of material misstatement due to fraud.
  3. Going concern uncertainty if conditions worsen.
  4. Termination of Resilient Cosme-Ceuticals acquisition.

Key Drivers

  1. Acquired Yash Pharma's India and Bhutan business.
  2. Broadening presence in the Indian market.
  3. Approved significant share buyback program.
  4. Recommended dividend of Rs. 4 per share.

Auditor’s Report

  1. Unmodified Opinion on Audited (Standalone) Financial Results.

Board Commentary

  1. Recommended a dividend of Rs. 4/- (200%) per equity share for FY26.
  2. Impact of new Labour Codes (Code on Wages, Industrial Relations, Social Security, Occupational Safety) on employee benefits.
  3. Resulted in additional employee benefit expense of 20.79 million (exceptional item).
  4. Approved buy-back of up to 1,600,000 equity shares for up to 400 million rupees.

Corporate Governance

  1. Audit Committee reviewed financial results.
  2. Nomination and Remuneration Committee granted stock options.

Management Discussion & Analysis

Future Strategy

  1. Broadening presence in the Indian market through acquisitions.

Performance Drivers

  1. Increased profit before exceptional items and tax for FY26 compared to FY25.